Brief: Neurosense Confirms Favorable Safety And Tolerability Of Primec In An Alzheimer's Phase 2 Study
22/12/2025 14:20
Dec 22 (Reuters) - Neurosense Therapeutics Ltd NRSN.O: NEUROSENSE CONFIRMS FAVORABLE SAFETY AND TOLERABILITY OF PRIMEC IN AN ALZHEIMER'S PHASE 2 STUDY Source text: ID:nPn7B685ma Further company coverage: NRSN.O ((Reuters.Briefs@thomsonreuters.com;))